SCHEMBL6415856

SCHEMBL6415856

O=C(/C=C/c1ccccc1)NCCCCCCNC(=O)/C=C/c1ccccc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.90
EGFR P00533 1/20 0.85
HDAC3 O15379 3/20 0.80
HDAC4 P56524 3/20 0.80
HDAC1 Q13547 3/20 0.80
HDAC2 Q92769 3/20 0.80
HDAC8 Q9BY41 3/20 0.80
HDAC6 Q9UBN7 3/20 0.80
HDAC7 Q8WUI4 2/20 0.80
HDAC10 Q969S8 2/20 0.80
HDAC11 Q96DB2 2/20 0.80
HDAC9 Q9UKV0 2/20 0.80
HDAC5 Q9UQL6 2/20 0.80
MMP1 P03956 2/20 0.71
MMP2 P08253 2/20 0.71
MMP9 P14780 2/20 0.71
POLB P06746 1/20 0.71
RECQL P46063 1/20 0.71
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415859 1.00 KMT2A (0.90) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL25510255 1.00 KMT2A (0.90) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL3208177 0.98 KMT2A (0.93) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL25193280 0.95 KMT2A (1.00) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL27093047 0.94 KMT2A (0.79) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL27093062 0.94 KMT2A (0.79) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL27093034 0.94 KMT2A (0.79) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL25214026 0.92 KMT2A (0.77) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL25184085 0.92 KMT2A (0.77) KMT2AEGFRHDAC3HDAC4HDAC1
SCHEMBL25264834 0.92 KMT2A (0.77) KMT2AEGFRHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12128015-B2 APE/REF1 inhibitors for the treatment of cancer CHAPMAN UNIVERSITY (US) 2024-10-29 US disclosed
US-20230157978-A1 APE/REF1 INHIBITORS FOR THE TREATMENT OF CANCER CHAPMAN UNIVERSITY 2023-05-25 US disclosed
US-10030176-B2 Electrically conductive adhesives comprising fluoroelastomers E I DU PONT DE NEMOURS AND COMPANY (US) 2018-07-24 US disclosed
EP-1235107-B1 Photopolymerizable composition FUJIFILM CORP (JP) 2016-11-09 EP disclosed
US-20150353779-A1 ELECTRICALLY CONDUCTIVE ADHESIVES COMPRISING FLUOROELASTOMERS SOLAR PASTE, LLC 2015-12-10 US disclosed
WO-2014110238-A1 ELECTRICALLY CONDUCTIVE ADHESIVES COMPRISING FLUOROELASTOMERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2014-07-17 WO disclosed
US-6838222-B2 Recording negatives; lithography printing plates; mixture of addiiton polymer and binder FUJI PHOTO FILM CO., LTD. (JP) 2005-01-04 US disclosed
US-20020160295-A1 Recording negatives; lithography printing plates; mixture of addiiton polymer and binder FUJIFILM CORPORATION (JP) 2002-10-31 US disclosed
EP-1235107-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 2002-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157978-A1 APE/REF1 INHIBITORS FOR THE TREATMENT OF CANCER APEX1, AP1G1, AP1M1 KMT2A 1945/4885EGFR 2189/4885HDAC3 2293/4885
US-12128015-B2 APE/REF1 inhibitors for the treatment of cancer APEX1, AP1G1, AP1M1 KMT2A 1945/4885EGFR 2189/4885HDAC3 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.